Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion

CONCLUSION: The findings from the three experiments in this study suggest that disclosures have the potential to increase relevant knowledge, but more research is needed to establish best practice recommendations for using disclosures to convey contextual information relevant for interpreting data displays in promotional communications.IMPLICATIONS FOR PRACTICE: Our manuscript reports the results from three large, online experimental studies that address a growing concern that drug companies often share favorable clinical trial results with physicians in promotional materials that lack important context for physicians to interpret the data. Our series of studies investigates whether strategic use of two types of disclosures (disclosure of data limitations and a disclosure of clinical uncertainty) improve understanding and reduce misinterpretations among physicians. The results from these studies help identify communication factors that impact how physicians critically appraise preliminary or exploratory clinical trial data to inform policy and regulatory efforts.PMID:34510619 | DOI:10.1002/onco.13972
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research